Add-On Nab-Paclitaxel Extends Survival in Metastatic Pancreatic Cancer

SAN FRANCISCO (IMNG) - Median overall survival in 861 patients with metastatic pancreatic cancer increased from 6.7 months in those randomized to gemcitabine therapy to 8.5 months in patients receiving...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news